Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105 SEK | +1.94% | +0.96% | +33.59% |
04-25 | Devyser Receives IVDR Approval for Post-Transplant Monitoring Software | CI |
03-11 | Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test | CI |
Sales 2024 * | 250M 22.84M 31.22M | Sales 2025 * | 342M 31.29M 42.78M | Capitalization | 1.71B 156M 214M |
---|---|---|---|---|---|
Net income 2024 * | -3M -274K -375K | Net income 2025 * | 37M 3.38M 4.62M | EV / Sales 2024 * | 5.99 x |
Net cash position 2024 * | 214M 19.56M 26.74M | Net cash position 2025 * | 228M 20.83M 28.49M | EV / Sales 2025 * | 4.33 x |
P/E ratio 2024 * |
-457
x | P/E ratio 2025 * |
43.5
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.4% |
Latest transcript on Devyser Diagnostics AB
1 day | +1.94% | ||
1 week | +0.96% | ||
Current month | +3.45% | ||
1 month | +3.96% | ||
3 months | +17.98% | ||
6 months | +71.01% | ||
Current year | +33.59% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Axel Klangby
FOU | Founder | 55 | 03-12-31 |
Fredrik Alpsten
CEO | Chief Executive Officer | 58 | - |
Sabina Berlin
DFI | Director of Finance/CFO | 41 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 20-12-31 | |
Director/Board Member | 52 | 21-12-31 | |
Chairman | 55 | 09-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 105 | +1.94% | 2,387 |
24-04-25 | 103 | +0.49% | 4,243 |
24-04-24 | 102.5 | -1.44% | 455 |
24-04-23 | 104 | +1.46% | 12,234 |
24-04-22 | 102.5 | -1.44% | 4,039 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.59% | 156M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- DVYSR Stock